This association has been recognized for years and forms the basis for clinical practice guidelines that recommend efforts to identify patients with cirrhosis and then to survey them every 6 months using a liver ultrasound (US) with/without alpha-fetoprotein (AFP) in order to detect HCC at an early treatable stage [3,4,5]. The gene discussed is AFP; the disease is hepatocellular carcinoma.